Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Northern Trust Corp raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 482,815 shares of the company’s stock after buying an additional 49,173 shares during the quarter. Northern Trust Corp owned approximately 0.63% of Trevi Therapeutics worth $1,989,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Boothbay Fund Management LLC purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth approximately $387,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth approximately $10,300,000. Price T Rowe Associates Inc. MD raised its stake in shares of Trevi Therapeutics by 32.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company’s stock worth $104,000 after purchasing an additional 6,119 shares during the last quarter. Silverarc Capital Management LLC raised its stake in shares of Trevi Therapeutics by 52.1% during the fourth quarter. Silverarc Capital Management LLC now owns 734,234 shares of the company’s stock worth $3,025,000 after purchasing an additional 251,659 shares during the last quarter. Finally, Vivo Capital LLC raised its stake in shares of Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock worth $14,370,000 after purchasing an additional 1,875,000 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jennifer L. Good sold 5,263 shares of the firm’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $1,403,599.54. This represents a 2.41% decrease in their position. The disclosure for this sale can be found here. 18.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on TRVI shares. B. Riley restated a “buy” rating and set a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Oppenheimer upped their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $12.50 price target on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a “buy” rating and set a $24.00 price target on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. Finally, D. Boral Capital restated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $6.29 on Monday. Trevi Therapeutics, Inc. has a one year low of $2.30 and a one year high of $7.39. The business has a fifty day moving average of $6.27 and a two-hundred day moving average of $4.77. The company has a market cap of $628.33 million, a P/E ratio of -14.30 and a beta of 0.62.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. Sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.